Characterization of Epithelial Ovarian Cancer Patients in Terms of Homologous Recombination Phenotype

This study is characterizing the genetics and biology of epithelial ovarian cancer in patients who are starting platinum-based chemotherapy. Researchers are particularly focused on understanding a DNA repair pathway (homologous recombination) that affects how tumors respond to treatment. **You may be eligible if...** - You are a woman 18 or older - You have been newly diagnosed with epithelial ovarian cancer (confirmed by biopsy) - Your cancer is either: early stage (FIGO I-II) with a known BRCA1/2 mutation, OR advanced stage (FIGO III-IV) of any type - You are scheduled to receive platinum-based chemotherapy - You can provide a tumor tissue sample **You may NOT be eligible if...** - You have a non-epithelial type of ovarian cancer (e.g., borderline tumor) - You are unable to provide consent or comply with the study requirements Talk to your doctor to see if this trial is right for you.